Core Viewpoint - Walgreens Boots Alliance reported a narrower-than-expected loss of $175 million in its third quarter, as the company approaches the end of its tenure as a publicly traded entity [2][3]. Financial Performance - For the fiscal third quarter ending May 31, Walgreens experienced a 7% increase in sales, reaching $39 billion, despite a loss of $175 million, which is a decrease of $519 million compared to net earnings of $344 million in the same period last year [3]. - The U.S. Retail Pharmacy segment sales rose nearly 8% to $39.7 billion compared to the previous year, although retail sales within that segment decreased by 5%, leading to a 30% drop in adjusted operating income to $350 million from $501 million [5]. Strategic Developments - Walgreens is in the process of completing a sale to Sycamore Partners for over $10 billion, with a special shareholder meeting scheduled for July 11 to vote on the deal [3][4]. - The Sycamore deal includes a payment of $11.45 per share, which is 29% above the stock price from December [4]. - The total value of the Sycamore deal exceeds $23 billion when including debt and other items [7]. Operational Challenges - The company has faced significant challenges, including a disastrous rollout of in-store clinics, leading to numerous pharmacy closures and a decline in stock value [4][9]. - Walgreens has lost more than $3.2 billion, or $3.81 per share, for the nine-month period ending May 31, compared to a loss of $5.6 billion, or $6.53 per share, in the previous year [10]. Future Outlook - The CEO emphasized the need for a turnaround plan that requires time and a balanced approach to manage future cash needs while making necessary investments [6].

Sales Performance - Sales for the three months ended May 31, 2025 increased 7.8% to $6.2 billion, with a favorable impact of currency translation of 1.9 percentage points [274]. - For the nine months ended May 31, 2025, sales increased 6.1% to $18.7 billion, with a constant currency increase of 5.5% [285]. - Pharmacy sales increased 4.6% in the same period, with comparable pharmacy sales in constant currency rising 5.8% [275]. - Retail sales grew 7.4%, driven by strong performance in Boots UK, with Boots.com sales increasing 18.7% [276]. - Pharmacy sales decreased 1.3% for the nine months, but comparable pharmacy sales in constant currency increased 5.8% [286]. - Retail sales for the nine months increased 5.8%, with Boots.com sales growing 23.1% [287]. - The U.S. Healthcare segment reported sales of $2.1 billion for the three months ended May 31, 2025, with an adjusted operating income of $54 million [297]. - Sales for the three months ended May 31, 2025, decreased by $23 million to $2.1 billion, a decline of 1.1% year-over-year, primarily due to lower revenue at VillageMD [298]. - Sales for the nine months ended May 31, 2025, increased by $195 million to $6.4 billion, with CareCentrix sales up 11.3% and Shields sales up 28.1% [304]. Operating Income and Profitability - Operating income for the three months ended May 31, 2025 increased 31.1% to $188 million, favorably impacted by currency translation [282]. - Adjusted operating income for the same period rose 22.0% to $214 million, reflecting strong retail performance and market growth [283]. - Gross profit for the three months ended May 31, 2025, was $256 million, an increase of $75 million compared to the same quarter last year, reflecting higher contributions from VillageMD and Shields [299]. - Adjusted operating income for the nine months ended May 31, 2025, improved by $346 million to $196 million, supported by contributions from VillageMD and Shields [308]. - Adjusted EBITDA for the three months ended May 31, 2025, was $86 million, an increase of $63 million compared to the prior year, reflecting improvements at VillageMD and Shields [303]. - Adjusted EBITDA for the nine months ended May 31, 2025, was $314 million, an increase of $313 million compared to the previous year, indicating significant growth at VillageMD and Shields [309]. - The operating loss for the three months ended May 31, 2025, was $64 million, a decrease of $156 million from the prior year, reflecting lower acquisition-related amortization [301]. - The operating loss for the nine months ended May 31, 2025, was $3.7 billion, a decrease of $10.0 billion compared to the previous year, due to higher contributions from VillageMD and Shields [307]. Net Earnings and Losses - For the three months ended May 31, 2025, Walgreens Boots Alliance reported a net loss of $175 million compared to a net earnings of $344 million in the same period of 2024 [322]. - Adjusted net earnings attributable to Walgreens Boots Alliance for the three months ended May 31, 2025, were $334 million, down from $545 million in the same period of 2024, representing a decrease of approximately 38.6% [324]. - The diluted net loss per common share for the three months ended May 31, 2025, was $(0.20), compared to diluted net earnings per share of $0.40 in the same period of 2024 [324]. Cash Flow and Debt Management - The Company reported net cash provided by operating activities of $245 million for the nine months ended May 31, 2025, compared to a net cash used of $314 million for the same period in 2024, indicating a significant improvement [350]. - As of May 31, 2025, the Company had outstanding total debt of $7.4 billion, with $429 million classified as current, and approximately $1.8 billion and $846 million of this debt due in fiscal 2026 and 2027, respectively [341]. - The Company suspended its quarterly cash dividends to strengthen its balance sheet and improve free cash flow, focusing on debt reduction and capital allocation [332]. - The Company executed a sale of 1.3 million shares of Cencora for approximately $315 million, with proceeds used to pay down debt and for general corporate purposes [339]. - The Company entered into an accounts receivable securitization facility with an initial borrowing capacity of $2.5 billion to repay outstanding borrowings [342]. - The Company recorded pre-tax gains of $10 million and $135 million related to the change in classification of its previously held equity method investment in BrightSpring during the three and nine months ended May 31, 2025 [330]. - The Company continues to explore strategic monetization of non-core assets to provide additional liquidity, including VPF derivative contracts related to Cencora common stock [336]. - Net cash used for financing activities for the nine months ended May 31, 2025 was $2.8 billion, compared to $912 million in the prior year, with $25.0 billion in proceeds from debt [356]. - Total debt payments for the nine months ended May 31, 2025 amounted to $27.2 billion, an increase from $23.1 billion in the previous year, including significant repayments on various credit facilities [357]. Strategic Initiatives and Future Outlook - The Company continues to focus on strategic capital allocation and improving free cash flow amid ongoing financial challenges [359]. - The Company has accrued a total liability of $6.2 billion associated with the Multistate Settlement Agreement and other opioid-related claims, with $650 million and $5.5 billion classified in accrued expenses and other liabilities, respectively [345]. - The Company expects to make remaining contributions of approximately $450 million related to the Bulk Purchase Annuity Agreement by the end of fiscal 2026 [347]. - The Company recorded professional services and other transaction-related expenses of $15 million related to the merger agreement with Blazing Star Parent, LLC, during the three months ended May 31, 2025 [327]. - As of May 31, 2025, the Company's long-term credit ratings were Ba3 from Moody's and BB- from Standard & Poor's, with a negative outlook from S&P [364]. - The Company has repurchased $8.0 billion of its common stock under a program authorized for up to $10.0 billion, although repurchases were suspended in July 2020 [360]. - The Company received cash proceeds of $103 million from settling VPF derivative contracts through the delivery of 2.2 million shares of Cencora common stock in the nine months ended May 31, 2025 [358].

Financial Performance - Third quarter sales increased 7.2% year-over-year to $39.0 billion, with a 6.9% increase on a constant currency basis[6] - Third quarter loss per share was $0.20, compared to earnings per share of $0.40 in the year-ago quarter, reflecting a decline of 150%[7][11] - Adjusted earnings per share decreased to $0.38 from $0.63 in the year-ago quarter, a decline of 39.6% on a constant currency basis[7][11] - Net loss for the third quarter was $175 million, a decrease of $519 million compared to net earnings of $344 million in the year-ago quarter[9] - Adjusted operating income for the third quarter was $558 million, down from $613 million in the year-ago quarter, reflecting lower U.S. retail sales[8] - The company has withdrawn fiscal 2025 guidance due to the pending acquisition by entities affiliated with Sycamore Partners[4][31] - For the nine months ended May 31, 2025, the net loss was $4,836 million, a significant improvement from a net loss of $12,370 million in the same period of 2024, representing a reduction of approximately 61.0%[50] - Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. for the nine months ended May 31, 2025, were $1,317 million, down from $2,152 million in 2024, a decrease of approximately 38.8%[62] Sales and Revenue - U.S. Retail Pharmacy segment sales were $30.7 billion, up 7.8% year-over-year, with comparable sales increasing 10.3%[20] - International segment sales reached $6.2 billion, a 7.8% increase from the year-ago quarter, with a 5.9% increase on a constant currency basis[24] - U.S. Healthcare segment sales were $2.1 billion, a decrease of $23 million, primarily due to a 6.5% decline in VillageMD sales[27] - Sales for the three months ended May 31, 2025, were $38,986 million, an increase from $36,351 million in the same period of 2024, representing a growth of 4.5%[46] - Total sales for the three months ended May 31, 2025, were $30,715 million, compared to $28,503 million for the same period in 2024, representing a growth of approximately 7.6%[67] - The U.S. Retail Pharmacy segment's sales for the nine months ended May 31, 2025, were $91,961 million, compared to $86,308 million for the same period in 2024, showing an increase of about 6.1%[67] Cash Flow and Liquidity - Net cash provided by operating activities was $584 million, a $20 million decrease compared to the year-ago quarter[12] - Cash flows from operating activities provided $245 million, compared to a cash outflow of $314 million in the prior year, indicating a positive turnaround[50] - The company reported a net cash provided by investing activities of $260 million, down from $1,106 million in the previous year, reflecting a decrease of approximately 76.5%[50] - The net cash used for financing activities was $2,785 million, compared to $912 million in the prior year, indicating a significant increase in cash outflow[50] - The cash, cash equivalents, and restricted cash at the end of the period were $939 million, an increase from $740 million at the end of the previous year[50] - The company experienced a net decrease in cash, cash equivalents, and restricted cash of $2,280 million for the nine months ended May 31, 2025, compared to a decrease of $117 million in the prior year[50] Assets and Liabilities - Total assets decreased to $69,406 million as of May 31, 2025, down from $81,037 million as of August 31, 2024, reflecting a decline of 14.3%[47] - Current liabilities were $25,958 million as of May 31, 2025, compared to $26,953 million as of August 31, 2024, showing a decrease of 3.7%[47] - The company’s cash and cash equivalents decreased to $766 million as of May 31, 2025, from $1,319 million as of August 31, 2024, a decline of 42%[47] - The company’s long-term debt decreased to $6,937 million as of May 31, 2025, from $8,044 million as of August 31, 2024, a reduction of 13.8%[47] Impairments and Adjustments - The company reported an operating loss of $5,759 million for the nine months ended May 31, 2025, an improvement from a loss of $13,099 million in the same period of 2024[46] - The company recognized impairment of goodwill and intangibles amounting to $89 million for the three months ended May 31, 2025[68] - The company reported a total impairment of goodwill, intangibles, and long-lived assets of $5,432 million for the nine months ended May 31, 2025[68] - The company’s impairment of goodwill, intangibles, and long-lived assets for the nine months ended May 31, 2025, was $6,195 million, down from $13,091 million in 2024, indicating a reduction of approximately 52.7%[62] - The Company recorded professional services and other transaction-related expenses of $15 million and $50 million for the three and nine months ended May 31, 2025, related to the merger agreement with Blazing Star Parent, LLC[65] Employment and Operations - Walgreens Boots Alliance employs approximately 312,000 people across eight countries, maintaining a significant presence in the healthcare ecosystem[41]

Group 1 - Walgreens Boots Alliance, Inc. is set to release its third-quarter earnings results on June 26, with analysts expecting earnings of 34 cents per share, a decrease from 63 cents per share in the same period last year [1] - The company is projected to report quarterly revenue of $36.72 billion, slightly up from $36.35 billion a year earlier [1] - On April 21, Walgreens announced a $300 million settlement to resolve federal allegations regarding the filling of invalid prescriptions for opioids and other controlled substances [2] Group 2 - Deutsche Bank analyst downgraded Walgreens stock from Hold to Sell, reducing the price target from $11 to $9 [5] - Truist Securities maintained a Hold rating but lowered the price target from $13 to $12 [5] - UBS analyst maintained a Neutral rating and raised the price target from $9 to $10 [5] - Morgan Stanley maintained an Underweight rating and cut the price target from $9 to $7 [5]

Core Insights - Rite Aid is undergoing bankruptcy proceedings, with various companies, including Walgreens and brand management firms, evaluating its remaining assets [1][4][9] - Kourtney Kardashian has shown interest in acquiring Rite Aid's Thrifty ice cream brand, which has a history dating back to 1940 [3][7] Group 1: Bankruptcy and Asset Evaluation - Rite Aid operates approximately 1,200 stores and serves around 8 million customers, having filed for bankruptcy for the second time in two years [4][8] - The bankruptcy judge has approved store closures and the sale of customer prescription files to 13 buyers, including CVS Health and Walgreens [4][10] - Brand management companies such as Authentic Brands Group, WHP Global, and Marquee Brands are assessing Rite Aid's intellectual property and loyalty program [1][2] Group 2: Interest in Thrifty Ice Cream Brand - Kourtney Kardashian, co-founder of Lemme and owner of Poosh, is interested in Rite Aid's Thrifty ice cream brand, which is sold at various retailers [3][5][6] - Thrifty ice cream has a notable history and has attracted interest from consumer-focused private equity firms as well [7]

Company Performance - Walgreens Boots Alliance (WBA) stock closed at $11.20, reflecting a -0.44% change compared to the previous day, underperforming the S&P 500 which gained 0.41% [1] - Over the past month, WBA shares appreciated by 2.46%, lagging behind the Retail-Wholesale sector's gain of 5.64% and the S&P 500's gain of 6.13% [1] Earnings Report Expectations - The upcoming earnings report for WBA is projected to show earnings of $0.34 per share, indicating a year-over-year decline of 46.03% [2] - Revenue is anticipated to be $36.66 billion, representing a 0.85% increase from the same quarter last year [2] Full Year Projections - For the full year, earnings are estimated at $1.66 per share, reflecting a -42.36% change from the previous year, while revenue is projected at $151.49 billion, showing a +2.59% change [3] Analyst Estimates and Stock Performance - Recent changes to analyst estimates for WBA suggest evolving short-term business trends, with positive revisions indicating optimism about the company's outlook [3] - The Zacks Rank system, which incorporates estimate changes, currently ranks WBA at 3 (Hold) [5] Valuation Metrics - WBA has a Forward P/E ratio of 6.77, which is a premium compared to its industry's Forward P/E of 5.43 [6] - The PEG ratio for WBA stands at 1.35, while the average PEG ratio for Retail - Pharmacies and Drug Stores stocks is 0.79 [7] Industry Context - The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector and holds a Zacks Industry Rank of 3, placing it in the top 2% of over 250 industries [8]

Core Viewpoint - Walgreens Boots Alliance Inc (WBA) has been experiencing stagnant stock performance, particularly following the announcement of a $10 billion deal to take the company private by Sycamore Partners, with the stock currently priced at $11.21 [1] Group 1: Stock Performance - WBA has been identified as the worst-performing stock in the S&P 500 Index for the month of June over the past decade, averaging a loss of 3.7% and finishing lower 80% of the time [2] - The average return for WBA in June is -3.69%, with a median return of -1.63%, and only 20% of the time has it posted a positive return [3] Group 2: Analyst Sentiment - Among the 15 analysts covering WBA, only two have a "buy" rating, while 11 maintain a "hold" rating, indicating potential for downgrades that could negatively impact the stock [4] - The current call/put volume ratio for WBA is 4.57, which is higher than 84% of readings from the past year, suggesting a high level of optimism in the options market [4] Group 3: Options Market - The Schaeffer's Volatility Index (SVI) for WBA is at 23%, ranking in the low 12th percentile of its annual range, indicating that options traders are expecting low volatility [5] - Historically, WBA has outperformed these low volatility expectations, as reflected in its Schaeffer's Volatility Scorecard (SVS) score of 81 out of 100 [5]

Company Overview - Walgreens Boots Alliance, Inc. (WBA) has opened a new micro-fulfillment center (MFC) in Brooklyn Park, MN, aimed at streamlining prescription processing and enhancing personalized care for patients [1] - The MFC will support nearly 200 Walgreens stores across the Midwest, processing approximately 13 million prescriptions annually and creating over 175 jobs in the area [2] Operational Efficiency - Walgreens operates a network of 12 MFCs that support over 5,000 stores in the U.S., fulfilling more than 3.5 million prescriptions weekly, resulting in a 24% year-over-year increase in shipped volumes [3] - Approximately 40% of a store's total prescription volume is managed by MFCs, which also implemented a recycling program that recycled 3.7 million pounds of materials in fiscal 2024 [4] Industry Prospects - The retail pharmacy market is projected to reach $640 billion by 2033, growing at a compound annual growth rate of 3.5% from 2026 to 2033, driven by an aging population and increased demand for healthcare services [5] Financial Performance - Year-to-date, WBA's shares have increased by 19.8%, outperforming the industry's growth of 18.3% and the S&P 500's rise of 0.2% during the same period [6] Market Position - Walgreens currently holds a Zacks Rank of 3 (Hold), indicating a stable market position [7]

Core Insights - Walgreens is increasing its investment in robotics with a new micro-fulfillment center in Minnesota, which will support nearly 200 locations and process approximately 13 million prescriptions annually [1][4] - The micro-fulfillment centers allow pharmacists to focus more on patient care rather than prescription filling, enhancing community health and patient experience [2][5] - The company operates a network of 12 micro-fulfillment centers that fulfill over 3.5 million prescriptions weekly, supporting more than 5,000 stores nationwide [3][4] Operational Efficiency - The micro-fulfillment centers have resulted in a 24% year-over-year increase in shipped volumes, with around 16 million prescriptions filled monthly [4][5] - In October 2023, these centers supported 4,300 locations, increasing to 4,800 by February 2024, handling 40% of the prescription volume at supported pharmacies [4][5] Industry Context - Other major retailers like Walmart and Amazon are also investing in robotics for fulfillment, with Amazon introducing a robot capable of sensing touch and Walmart utilizing robotic 3D printing technology for warehouse construction [6][7]

Company Performance - Walgreens Boots Alliance (WBA) closed at $11.18, with a daily gain of +0.45%, outperforming the S&P 500's gain of 0.41% [1] - The stock has increased by 3.06% over the past month, but this is below the Retail-Wholesale sector's gain of 9.47% and the S&P 500's gain of 9% [1] Upcoming Earnings - The upcoming earnings release is expected to show an EPS of $0.34, reflecting a 46.03% decline compared to the same quarter last year [2] - Revenue is anticipated to be $36.66 billion, indicating a 0.85% increase from the same quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $1.66 per share, representing a -42.36% change from the prior year [3] - Revenue for the fiscal year is estimated at $151.49 billion, showing a +2.59% change from the previous year [3] Analyst Estimates - Recent changes to analyst estimates indicate positive short-term business trends, which are generally viewed as favorable for the company's outlook [4] - The Zacks Rank system, which incorporates estimate changes, suggests actionable ratings based on these revisions [5] Zacks Rank and Valuation - Walgreens Boots Alliance currently holds a Zacks Rank of 3 (Hold), with a 0.88% rise in the Zacks Consensus EPS estimate over the past month [6] - The company has a Forward P/E ratio of 6.7, which is a premium compared to the industry average of 5.11 [7] PEG Ratio - The PEG ratio for Walgreens Boots Alliance is 1.34, compared to the industry average PEG ratio of 0.77 [8] - The Retail - Pharmacies and Drug Stores industry is ranked in the top 1% of all industries according to the Zacks Industry Rank [8][9]